Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.

Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. Eur J Cancer. 2021 11; 157:415-423.

View in: PubMed

subject areas

Aged
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
BRCA1 Protein
BRCA2 Protein
Double-Blind Method
Female
Follow-Up Studies
Humans
Maintenance Chemotherapy
Middle Aged
Mutation
Neoplasm Staging
Ovarian Neoplasms
Phthalazines
Piperazines
Placebos
Poly(ADP-ribose) Polymerase Inhibitors
Response Evaluation Criteria in Solid Tumors

authors with profiles

Kathleen Moore